# Navi Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/navi-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Series A (Aug 18, 2026)
- Investors on record: 6

## About

Founded in 2024 and based in Shanghai, China, Navi Therapeutics (Shanghai) Co., Ltd., trading as Navi Therapeutics, conducts scientific research and experimental development in medicine, with operations extending to health consultation and bio-chemical technology R&D. The company aims to promote innovation in biological drug production and integrate advanced biomedical technologies into its product pipeline. In August 2026, Navi Therapeutics raised a Series A funding co-led by Legend Capital and Kangjun Capital, with participation from YuanBio Venture, Trinity Innovation Fund, Oriza Holdings, Tingyu Fund, and other investors.

Navi Therapeutics develops and manufactures biological drugs and bio-based pharmaceutical materials. Its services include medical research and clinical experimental development, biotechnological process innovation, and technical consulting in healthcare. 

The company will use the latest funding to advance preclinical research on two First-in-Class ADC candidates and complete all preparations for IND application; iterate and upgrade the two core proprietary technology platforms, NaviMIG® multi-antibody platform and ReviLOAD® payload; continuously improve the AI-driven ADC closed-loop R&D system and strengthen the linkage between algorithms and experimental data; and attract high-end R&D talent in multiple fields, including antibodies, AI, clinical practice, and CMC, to solidify the company's long-term innovation foundation.

## Funding rounds

- Series A, Aug 18, 2026 — Legend Capital, Oriza Holdings, YuanBio Venture, Trinity Innovation Fund, Kangjun Capital, Tingyu Fund

## Investors

- Legend Capital — Series A
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Series A
- Kangjun Capital (https://capitalatlas.ai/funds/kangjun-capital) — Series A
- Tingyu Fund — Series A